Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP
Corbus Pharmaceuticals — Investor Presentation (November 2019)
46 slides from Corbus Pharmaceuticals's investor presentation, Nov 25, 2019
Slide 1: Pioneering transformative medicines that target the endocannabinoid system
@ Pioneering transformative medicines that target the re endocannabinoid system PHARMACEUTICALS
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains certain forward-looking statements, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, bus
Slide 3: ‘wood
‘wood orwood, MA Additional awards and Upfront payment from grants from NIH and CFF Kaken collaboration
Slide 4: Label Extension
0.98 0.96 0,96 0.95 0.95 7 r Label Extension Open-! 0.70 0.63 0.58 Weeks 12 20 28 36 44 52 60 68 76 84 92 100108 iy i © i @ Beg 2 a 4 a a z i =e nee E> juaaied uelpau ‘a109g sido NOW
Slide 5: Oral new chemical entity (NCE)
Oral new chemical entity (NCE) G protein-coupled receptors (GPCRs) activation (CB2) Resolves inflammation Limits fibrosis IP until 2034 ~e Lenabasum molecule (purple) SS Highlighted H-bond interaction (yellow dashed line) pi stacking interaction (blue dashed line)
Slide 6: What is the Endocannabinoid System (ECS)?
What is the Endocannabinoid System (ECS)? 2 related GPCRs (CB1 and CB2) Endogenous agonists (Anandamide and 2-AG) Metabolic enzymes (FAAH and MAGL) CBI | CB2 * Mostly in CNS s:+ © Mostly in immune system Analgesic, anti-emetic, euphoric, Anti-inflammatory and anti- appetite... fibrotic Also found in
Slide 7: Growing Recognition of Therapeutic Potential of Targeting the ECS
Growing Recognition of Therapeutic Potential of Targeting the ECS Company Drug Candidate Phase Target Type of Compound Lenabasum Phase 3 in SSc & DM CORBUS , (CB2 agonist) Nemeoicee Te SSe, DM, CF & SLE Small molecule (NCE) PHARHACEDTICALS: CRB-4001 Phase 1 safety data expected (CBI inverse agonist)
Slide 8: Corbus Pipeline: Early and Late Stage Programs
Corbus Pipeline: Early and Late Stage Programs Preclinical Phase 1 Phase 2 Phase 3 Approval Fy Systemic Sclerosis Targeting a = Dermatomyositis 2021 2 Lenabasum Systemic Lupus Erythematosus CRB-4001 (>700 drug candidates) | Preclinical library | J
Slide 9: Strategic Optionality: Intellectual Property Rights for Lenabasum
Robust Domestic and Foreign Intellectual Property Rig r Lenabasum Provide Strategic Optionality I cimope = JAPAN PATIENT #) KAKEN PHARMACEUTICAL CO.,LTD. POPULATION": POPULATION’: . | SSc: 81,000 SSc: 28,000 | Japan partnerships es DM: 31,000 DM: 9,000 Kaken Pharmaceuticals a SLE: 240,000 SLE: 50,00
Slide 10: = S n o o ro 7) —
= S n o 2 o ro 7) —
Slide 11: Lenabasum - SSc: Systemic Sclerosis at a Glance
Lenabasum - SSc temic Sclerosis (SSc) at a Glance Rare and life-threatening autoimmune disease characterized by tissue inflammation and fibrosis ~200,000 | 40-60% Zero Orphan Drug Designation people with SSc in _ mortality in 10 years with severe SSc-specific aka . im U.S., EU and Japan? internal or
Slide 12: ACR CRISS Score
ACR CRISS Score Lenabasum - SSc Phase 2 Study: Improvement in Primary Endpoint Stable standard-of-care drugs, including immunosuppressive drugs DBPC Open-Label Extension 105 ogsoss 096 096 Ss? 0.94 = 084 8 4 Placebo DEPC 0.77 3 Lenabasum DEPC Zo? = OLE 0.70 £ 0.64 Placebo Abatacept Ph 2 0.63 8 .6-|
Slide 13: mRSS Score
mRSS Score Lenabasum - SSc Phase 2 Study: Improvement in Secondary Endpoints Stable standard-of-care drugs, including immunosuppressive drugs -4 to -5 points is generally considered minimal clinically DBPC Open-Label Extension 0 0.01 -0.01 a8 important difference (MCID)! Comparator trials -3.50' IE
Slide 14: Measurements Across All Domains of CRISS
Phase 2 Measurements Across All 5 Domains of CRISS Lenabasum - SSc e FVC% Predicted 4 £ oo Bu iz = 2 =. < a . 6 A SHRUGS OS MIPPHPIPSPSLPASE SHBDWE S HIPHHPI OPP ARS SHOWS SHIP PH PISH PAKS ‘Week ‘Week ‘Week Physician Global Assessment “15: SHWDS OC MIPHHPISSLPALRS Week T T T T SHOMS SMIPPPHPIPPLPAA
Slide 15: Change from Baseline in SSPRO and 5D-Itch
Phase 2 . Lenabasum - SSc Change from Baseline in SSPRO and 5D-Itch Skin Symptoms (SSPRO) 14 5D-Itch mean 20.2 vk wl SHG CHG PPL PISS LI HOES GHLMS CHIP PH PIPES LHI OGE Week Week
Slide 16: Patient Distribution of ACR CRISS Scores in Open-Label Extension Study
Patient Distribution of ACR CRISS Scores at Month 25 in Open-Label Extension Study Lenabasum - SSc 45% of subjects achieved CRISS score of 1.0 ACR CRISS Score 1.0 0.9: 0.8 0.7 0.6: 0.5: 0.4: 0.3 0.2 0.1 0.0 Individual ACR CRISS Scores NYVDRSOA TION GOK OM DWP Each Bar Represents an Individual Subjec
Slide 17: Lenabasum Treatment Findings of Skin Biopsies
Lenabasum Treatment aie weeds! Findings of Change from Baseline, % of Skin Biopsies 100% 80% 60% 40% 20% 0% Inflammation Placebo Lenabasum Placebo Lenabasum Lenabasum - SSc mlmproved mStable ™Worsened
Slide 18: Lenabasum Safety Overview
Lenabasum Lenabasum Safety Overview X Safety overview as of March 2019 The majority of adverse reactions observed in clinical studies conducted to date are mild or moderate Most common adverse reactions are transient dizziness and dry mouth, which are consistent with expected class effects 2 withdra
Slide 19: Ongoing Phase 3 RESOLVE-1 Study
Lenabasum - SSc Ongoing Phase 3 RESOLVE-1 Study Enrollment Complete | Topline Data Expected Summer of 2020 | Patent Protection Through 2034 Double-blind, randomized, placebo-controlled study 20 mg BID <) 2 5 mg BID Placebo Week study Multinational 365 subjects 1:1:1 dosing Primary Endpoint in U.S. &
Slide 20: Key Insights Provide Foundation for Commercial Strategy in SSc
Key Insights Provide Foundation for Commercial Strategy in SSc* Significant unmet need and no approved treatments for totality of disease * Often lengthy and challenging journey to diagnosis * Current therapies address symptoms or specific organ involvement only * No other drug candidates in late-st
Slide 21: Commercial Launch Team
Commercial Launch Team Craig Millian, MBA Chief Commercial Officer 25 years of experience leading commercial organizations for a range of pharmaceutical companies as well as a successful track record building pharmaceutical brands = WB sanort EMDSerono yrliex GE Brian Walsh, MBA Head, Global Marketi
Slide 22: Lenabasum - DM: Dermatomyositis at a Glance
Lenabasum - DM Dermatomyositis (DM) at a Glance Rare and life-threatening autoimmune disease characterized by skin and muscle inflammation ~80,000 people with DM in U.S., EU and Japan! 30% Zero Orphan Drug Designation mortality in DM-specific from FDA & EMA 5 years” drugs approved . : Schiopu et al,
Slide 23: CDASI Activity Score
CDASI Activity Score Phase 2 Clinically Meaningful Improvement in Skin & Other Outcomes ACDAS! Activity Score (Mean) DBPC. Open-Label Extension Lenabasum - DM 18/20 (90%) of subjects enrolled in the OLE were still enrolled after 23 months * Continued improvement in open-label extension study * 72% a
Slide 24: Distribution of CDASI Scores in Open-Label Extension Study
Distribution of CDASI Scores at Month 23 in Open-Label Extension Study Lenabasum - DM 72% achieved low skin disease activity (CDASI < 14) by Week 100 ACDAS! Activity Score & n -50: Individual CDASI Scores S & ow Xx Each Bar Represents an Individual Subject, Month 23 T T T T T T T T HF SF sh HF gh s©
Slide 25: Patient Activity Visual Analogue Scale Scores
Phase 2 . Lenabasum - DM Patient Activity Visual Analogue Scale Scores Disease Activity Skin Activity ‘A Patient Disease Activty 10-cm VAS (Mean) ‘A Patient Skin Activity 10-cm VAS (Mean) mean 31 wk ° tooo 0481216 0 4 12 20 28 36 44 52 60 68 76 84 92100 0 4 8 1216 0 4 12 20 28 36 44 52 60 68 76 84 9
Slide 26: Patient-Reported Outcomes
Phase 2 Patient-Repo ‘AltchVAS (Mean) ‘APROMIS-29 Physcial Function (Mean) Daan ‘0 4 42:20 28-36 44 52 GD GO 76 4 2100 Weeks ,, Promis-29 Physical Function — oa ets (0 4 12:20 20:36 44 52 G0 G8 76 84 $2100 Weeks PROMIS-29 Pain Interference A acebo DEP "© LeratasumDePC i “@ LenabasumOLE ‘ O48 Rte ‘04
Slide 27: Reduction in T Cell Infiltration in Skin Biopsies in DM
Lenabasum Treatment was Associated with Lenabasum - DM Reduction in T Cell Infiltration in Skin Biopsies in DM Associated with Improvement in CD4+ T Cells in Skin Biopsies Lenabasum Placebo Week 0 Week 12 Week 0 Week 12 15. J ns 15 40 10 oy 0 9 Paired biopsies from 6 lenabasum-treated - Week 0 12 0
Slide 28: Ongoing Phase 3 DETERMINE Study
Lenabasum - DM Ongoing Phase 3 DETERMINE Study Topline Data Expected 2021 | Patent Protection Through 2034 Double-blind, randomized, placebo-controlled study 20 mg BID 5 2 5 mg BID Placebo Week study Multinational ~150 subjects 2:1:2 dosing Primary Endpoint: American College of Rheumatology (ACR) /
Slide 29: CF: Targeting Pulmonary Exacerbations
Lenabasum - CF CF: Targeting Pulmonary Exacerbations (PEx) fa Seo 18 days 2.9 pulmonary spent in the hospital each -| year by average person with exacerbations per year2 cystic fibrosis (CF)! per person & Need for drugs to reduce pulmonary Up to C/ @ exacerbations $120k €® cost of pulmonary Pulmonar
Slide 30: Longer Time to PEx in Phase 2 Study
Survival Probability Lenabasum Treatment was Associated with Longer Time to PEx in Phase 2 Study (n = 85) 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 Lenabasum 61 Placebo 24 Lenabasum - CF Kaplan-Meier Survival Time Without a PEx +Censored Days PEx Free
Slide 31: Ongoing CF Phase 2b Study
Lenabasum - CF Ongoing CF Phase 2b Study Enrollment Complete | Topline Data Expected Summer of 2020 | Patent Protection Through 2034 Double-blind, randomized, placebo-controlled study 20 mg BID 26 5mg BID Placebo Week study Multinational 426 subjects 2:1:2 dosing Primary Endpoint: Event rate of PEx
Slide 32: Ongoing Systemic Lupus Erythematosus Phase 2 Study
Ongoing Systemic Lupus Erythematosus Phase 2 Study Lenabesum ~ SLE Funded and Run by National Institutes of Health Topline Data Expected 2020 | Patent Protection Through 2034 Double-blind, randomized, placebo-controlled study 20 mg BID 16 20 mg QD iv 5 mg BID Placebo Week study 15 sites in U.S. ~100
Slide 33: CRB-4001: Targeting NASH Using the Endocannabinoid System
CRB-4001 Targeting NASH Using the Endocannabinoid System
Slide 34: 2006: Targeting CB1 for Metabolism was Highly Desirable
2006: Targeting CB1 for Metabolism was Highly Desirable Drug Name Company Stage ~ Rimonabant iy SANOFI Launched in EU a Taranabant oe MERCK Phase 3 Otenabant Pfizer) phase’ e. Surinabant iy SANOFI Phase 2 Ibipinabant & Bristol-Myers Squibb Phase 2 Projected Annual Sales of Rimonabant were $3bn* 34 y
Slide 35: ...But It Ended Poorly in 2008
..But It Ended Poorly in 2008 35 AVE Doc. Ref. EMEA/CHMI PRESS RELEASE ‘The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia CB1 binding in the brain led to depression and suicidality Rimonabant (Acomplia) withdrawn Entire drug class terminated
Slide 36: 2019: Focusing on CB1 Without Affecting the Brain
CRB-4001 2019: Focusing on CB1 Without Affecting the Brain Company Compound Phase Type of compound D 4 Phase 1 safety data , - CORBUS \ CRB-4001 expected in 2020 CB1 inverse agonist Oral small molecule a Goldfinch Bio PoKaney car Preclinical : . GFB-024 (Phase 1 planned 2H 2020) CB1 antagonist Injec
Slide 37: CRB-4001 is an Attractive Candidate to Treat NASH
CRB-4001 CRB-4001 is an Attractive Candidate to Treat NASH CRB-4001 Blocks Metabolic Abnormalities and Reduces Biomarkers of Liver Damage Common in NASH Stimulates insulin release! Reduces body fat? Reduces liver fat? Insulin levels 4 vehicte Fatmass_ Lean mass Hepatic triglyceride (mg/g) 8 te Exd =
Slide 38: CRB-4001 Next Steps
CRB-4001 Next Steps
Slide 39: Corbus Platform
Corbus Platform Novel preclinical candidates that target the endocannabinoid system
Slide 40: Corbus Platform of Preclinical Drug Development
Endocannabinoid System Platform Corbus Platform of Preclinical Drug Development Phase 1 Toxicology In vivo testing In vitro testing In silico molecular modeling Library of rationally-designed “Docking” compounds into CB1 & CB2 compounds targeting the endocannabinoid system (>700 and growing)
Slide 41: First Group of Compounds Generated from Our Platform
Endocannabinoid System First Group of Compounds Generated from Our Platform Proprietary Platform in Preclinical Development IP protection until Cc B 1 Combats | a 2039 Novel CB1 Inverse Agonists CRB-4614 CRB-4496 CB2 Cannabinoid Receptor Type 2 Novel CB2 Agonists CRB-371 CRB-378 CRB-317 CRB-388 CRB-
Slide 42: Management Team with Proven Record of Execution
Corporate Overview Management Team with Proven Record of Execution Yuval Cohen, PhD Chief Executive Officer, Director More than 13 years of executive leadership experience in inflammatory disease drug development Sean Moran, CPA, MBA Chief Financial Officer More than 20 years of senior financial exp
Slide 43: Experienced and Engaged Board of Directors
Corporate Overview Experienced and Engaged Board of Director a Amb. Alan Holmer Ret. Chairman of the Board More than two decades of public service in Washington, D.C. including Special Envoy to China; Former CEO of PhRMA Avery W. (Chip) Catlin Director More than 25 years of senior financial leadersh
Slide 44: Financial Profile: CRBP (NASDAQ)
Financial Profile: CRBP (NASDAQ) Corporate Overview - $168M equity raised to-date - $45M non-dilutive funding from NIH and CF Foundation’ 64.6M Common shares outstanding 3, (78.4M fully diluted) x ek on ‘yee? COS erste, O $54.8M Cash balance as of 9/30/2019 4 $296M ey Market Cap? he a 3 a ne ei fet
Slide 45: Pioneering transformative medicines that target the endocannabinoid system
>" Pioneering transformative medicines that § () Li B US : target the endocannabinoid system PHARMACEUTICALS Corbus Pharmaceutical Holdings, Inc. 617.963.0100 info@corbuspharma.com
Slide 46: Consistent Reduction in Key Inflammatory Biomarkers (Sputum)
Consistent Reduction in Key Inflammatory Biomarkers (Sputum) Reduction with Lenabasum 20 mg BID Compared to Placebo (Log,,) p= 0.053 p= 0.089 25 -2 Neutrophils, cells/ml Eosinophils, cells/ml Lymphocytes, cells/ml Macrophages, cells/ml
Corbus Pharmaceuticals Holdings — Investor Presentation (November 2019) on 6ix